350 related articles for article (PubMed ID: 37841735)
21. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2.
Wu JL; Tseng WP; Lin CH; Lee TF; Chung MY; Huang CH; Chen SY; Hsueh PR; Chen SC
J Infect; 2020 Sep; 81(3):435-442. PubMed ID: 32553841
[TBL] [Abstract][Full Text] [Related]
22. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT).
Meyer B; Reimerink J; Torriani G; Brouwer F; Godeke GJ; Yerly S; Hoogerwerf M; Vuilleumier N; Kaiser L; Eckerle I; Reusken C
Emerg Microbes Infect; 2020 Dec; 9(1):2394-2403. PubMed ID: 33043818
[TBL] [Abstract][Full Text] [Related]
23. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
[TBL] [Abstract][Full Text] [Related]
24. Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.
Shurrab FM; Younes N; Al-Sadeq DW; Liu N; Qotba H; Abu-Raddad LJ; Nasrallah GK
Int J Infect Dis; 2022 May; 118():132-137. PubMed ID: 35231609
[TBL] [Abstract][Full Text] [Related]
25. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents.
Grant BD; Anderson CE; Williford JR; Alonzo LF; Glukhova VA; Boyle DS; Weigl BH; Nichols KP
Anal Chem; 2020 Aug; 92(16):11305-11309. PubMed ID: 32605363
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of qualitative and semi-quantitative cut offs for rapid diagnostic lateral flow test in relation to serology for the detection of SARS-CoV-2 antibodies: findings of a prospective study.
Peghin M; Bontempo G; De Martino M; Palese A; Gerussi V; Graziano E; Fabris M; D'Aurizio F; Sbrana F; Ripoli A; Curcio F; Isola M; Tascini C
BMC Infect Dis; 2022 Oct; 22(1):810. PubMed ID: 36316641
[TBL] [Abstract][Full Text] [Related]
28. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
Pieri M; Nicolai E; Nuccetelli M; Sarubbi S; Tomassetti F; Pelagalli M; Minieri M; Terrinoni A; Bernardini S
Arch Virol; 2022 May; 167(5):1285-1291. PubMed ID: 35377034
[TBL] [Abstract][Full Text] [Related]
29. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents.
Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Neil G; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
medRxiv; 2020 Aug; ():. PubMed ID: 32793928
[TBL] [Abstract][Full Text] [Related]
31. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.
Ferrari L; Ruggiero A; Stefani C; Benedetti L; Piermatteo L; Andreassi E; Caldara F; Zace D; Pagliari M; Ceccherini-Silberstein F; Jones C; Iannetta M; Geretti AM;
Sci Rep; 2024 Apr; 14(1):8337. PubMed ID: 38594459
[TBL] [Abstract][Full Text] [Related]
32. Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.
Horn MP; Jonsdottir HR; Brigger D; Damonti L; Suter-Riniker F; Endrich O; Froehlich TK; Fiedler M; Largiadèr CR; Marschall J; Weber B; Eggel A; Nagler M
Allergy; 2022 Jul; 77(7):2090-2103. PubMed ID: 34986501
[TBL] [Abstract][Full Text] [Related]
33. Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
Chan CW; Yi X; Lenza M; Baldwin AD; Jakalski J; Tesic V; Yeo KJ
Am J Clin Pathol; 2022 Jan; 157(1):109-118. PubMed ID: 34463315
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series.
Lee W; Kurien P
J Immunol Methods; 2023 Feb; 513():113410. PubMed ID: 36586509
[TBL] [Abstract][Full Text] [Related]
35. Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.
Lake DF; Roeder AJ; Kaleta E; Jasbi P; Pfeffer K; Koelbela C; Periasamy S; Kuzmina N; Bukreyev A; Grys TE; Wu L; Mills JR; McAulay K; Gonzalez-Moa M; Seit-Nebi A; Svarovsky S
J Clin Virol; 2021 Dec; 145():105024. PubMed ID: 34781240
[TBL] [Abstract][Full Text] [Related]
36. Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies.
Nakagama Y; Komase Y; Kaku N; Nitahara Y; Tshibangu-Kabamba E; Tominaga T; Tanaka H; Yokoya T; Hosokawa M; Kido Y
Microbiol Spectr; 2022 Aug; 10(4):e0098622. PubMed ID: 35867423
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer.
Cameron A; Bohrhunter JL; Porterfield CA; Mangat R; Karasick MH; Pearson Z; Angeloni S; Pecora ND
Microbiol Spectr; 2022 Apr; 10(2):e0250721. PubMed ID: 35389244
[TBL] [Abstract][Full Text] [Related]
38. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study.
To KK; Cheng VC; Cai JP; Chan KH; Chen LL; Wong LH; Choi CY; Fong CH; Ng AC; Lu L; Luo CT; Situ J; Chung TW; Wong SC; Kwan GS; Sridhar S; Chan JF; Fan CY; Chuang VWM; Kok KH; Hung IF; Yuen KY
Lancet Microbe; 2020 Jul; 1(3):e111-e118. PubMed ID: 33230504
[TBL] [Abstract][Full Text] [Related]
39. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
Fulford TS; Van H; Gherardin NA; Zheng S; Ciula M; Drummer HE; Redmond S; Tan HX; Boo I; Center RJ; Li F; Grimley SL; Wines BD; Nguyen THO; Mordant FL; Ellenberg P; Rowntree LC; Kedzierski L; Cheng AC; Doolan DL; Matthews G; Bond K; Hogarth PM; McQuilten Z; Subbarao K; Kedzierska K; Juno JA; Wheatley AK; Kent SJ; Williamson DA; Purcell DFJ; Anderson DA; Godfrey DI
EBioMedicine; 2021 Dec; 74():103729. PubMed ID: 34871960
[TBL] [Abstract][Full Text] [Related]
40. Analytical and Clinical Performance of Two Point of Care Rapid Antibody Assays for SARS-CoV-2.
Chakraborty B; Nath S; Deb S; Baruah A; Paul M; Dutta SS; Barbhuiya MA
Ann Clin Lab Sci; 2023 May; 53(3):353-359. PubMed ID: 37437941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
